Delivery of antiviral agents in liposomes

Methods in Enzymology

Volumn 391, Issue SPEC. ISS., 2005, Pages 351-373

  Düzgüneş, Nejat ^a   Simões, Sergio ^a   Slepushkin, Vladimir ^a   Pretzer, Elizabeth ^a   Flasher, Diana ^a   Salem, Isam I ^a   Steffan, Gerhard ^a   Konopka, Krystyna ^a   Pedroso De Lima, Maria C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 N MALEIMIDOPHENYL)BUTYRIC ACID HYDRAZIDE; ACETIC ACID DERIVATIVE; ACYCLIC NUCLEOSIDE; ADEFOVIR; ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; BUTYRIC ACID; CD4 ANTIGEN; CHOLESTEROL HYDROGEN SUCCINATE; CYCLODEXTRIN; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; HYDRAZIDE; IMIDE; LIPOSOME; MACROGOL; MALEIC ACID DERIVATIVE; METRIZAMIDE; N SUCCINIMIDYLACETYLTHIOACETATE; PHENYL GROUP; PHOSPHONIC ACID DERIVATIVE; PROTEIN A; PROTEINASE INHIBITOR; RIBOZYME; SUCCINIMIDE; TENOFOVIR; THIOACETIC ACID; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CORRELATION COEFFICIENT; CROSS COUPLING REACTION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULARY; DRUG POTENTIATION; DRUG PURIFICATION; DRUG SOLUBILITY; DRUG SPECIFICITY; DRUG STABILITY; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MICROENCAPSULATION; NONHUMAN; PH MEASUREMENT; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SPECTRAL SENSITIVITY; STRUCTURE ANALYSIS; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 13844254900     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0076-6879(05)91020-3     Document Type: Article

References (75)

1. Akhtar S., Rossi J.J. Anti-HIV therapy with antisense oligonucleotides and ribozymes: Realistic approaches or expensive myths? J. Antimicrob. Chemother. 38:1996;159-165
2. Aquaro S., Calio R., Balzarini J., Bellocchi M.C., Garaci E., Perno C.F. Macrophages and HIV infection: Therapeutical approaches toward this strategic virus reservoir. Antiviral Res. 55:2002;209-225
3. Ashkenazi A., Presta L.G., Marsters S.A., Camerato T.R., Rosenthal K.A., Fendly B.M., Capon D.J. Mapping the CD4 binding site for human immunodeficiency virus by alanine-scanning mutagenesis. Proc. Natl. Acad. Sci. USA. 87:1990;7150-7154
4. Balzarini J., Perno C.-F., Schols D., De Clercq E. Activity of acyclic nucleoside phosphonate analogues against human immunodeficiency virus in monocyte/macrophages and peripheral blood lymphocytes. Biochem. Biophys. Res. Commun. 178:1991;329-335
5. Bartlett G.R. Phosphorus assay in column chromatography. J. Biol. Chem. 234:1959;466-468
6. Bellanger N., Perly B. NMR investigations of the conformation of new cyclodextrin-based amphiphilic transporters for hydrophobic drugs: Molecular lollipops. J. Mol. Struct. 273:1992;215-226
7. Bennett C.F., Chiang M.Y., Chan H.C., Shoemaker J.E.E., Mirabelli C.K. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol. Pharmacol. 41:1992;1023-1033
8. Brand D., Srinivasan K., Sodroski J. Determinants of human immunodeficiency virus type 1 entry in the CDR2 loop of the CD4 glycoprotein. J. Virol. 69:1995;166-171
9. Capon D.J., Chamow S.M., Mordenti J., Marsters S.A., Gregory T., Mitsuya H., Byrn R.A., Lucas C., Wurm F.M., Groopman J.E., Broder S., Smith D.H. Designing CD4 immunoadhesins for AIDS therapy. Nature. 337:1989;525-531
10. Chamow S.M., Peers D.H., Byrn R.A., Mulkerrin M.G., Harris R.J., Wang W.-C., Bjorkman P.J., Capon D.J., Ashkenazi A. Enzymatic cleavage of a CD4 immunoadhesin generates crystallizable, biologically active Fd-like fragments. Biochemistry. 29:1990;9885-9891
11. Chamow S.M., Kogan T.P., Peers D.H., Hastings R.C., Byrn R.A., Ashkenazi A. Conjugation of soluble CD4 without loss of biological activity via a novel carbohydrate-directed cross-linking reagent. J. Biol. Chem. 267:1992;15916-15922
12. De Clercq E. Potential drugs for the treatment of AIDS. J. Antimicrob. Chemother. 23:(Suppl. A):1989;35-46
13. De Clercq E. Antiviral therapy for human immunodeficiency virus infections. Clin. Microbiol. Rev. 8:1995;200-239
14. De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin. Microbiol. Rev. 16:2003;569-596
15. Derksen J.T.P., Scherphof G.L. An improved method for the covalent coupling of proteins to liposomes. Biochim. Biophys. Acta. 814:1985;151-155
16. Duncan J.S., Weston P.D., Wrigglesworth R. A new reagent which may be used to introduce sulfhydryl groups into proteins, and its use in the preparation of conjugates for immunoassay. Anal. Biochem. 132:1983;68-73
17. Düzgüneş N. Treatment of human immunodeficiency virus, Mycobacterium avium and Mycobacterium tuberculosis infections by liposome-encapsulated drugs. Lasic D.D., Papahadjopoulos D. "Medical Applications of Liposomes" 1998;189-219 Elsevier Science B. V., Amsterdam
18. Düzgüneş N. Preparation and quantitation of small unilamellar liposomes and large unilamellar reverse-phase evaporation liposomes. Methods Enzymol. 367:2003;23-27
19. Düzgüneş N., Wilschut J., Hong K., Fraley R., Perry C., Friend D.S., James T.L., Papahadjopoulos D. Physicochemical characterization of large unilamellar vesicles prepared by reverse-phase evaporation. Biochim. Biophys. Acta. 732:1983;289-299
20. Düzgüneş N., Straubinger R.M., Baldwin P.A., Papahadjopoulos D. pH-sensitive liposomes: Introduction of foreign substances into cells. Wilschut J., Hoekstra D. "Membrane Fusion" 1991;713-730 Marcel Dekker, New York
21. Düzgüneş N., Flasher D., Pretzer E., Konopka K., Slepushkin V.A., Steffan G., Salem I.I., Reddy M.V., Gangadharam P.R.J. Liposome-mediated therapy of human immunodeficiency virus type-1 and Mycobacterium infections. J. Liposome Res. 5:1995;669-691
22. Düzgüneş N., Pretzer E., Simões S., Slepushkin V., Konopka K., Flasher D., Pedroso de Lima M.C. Liposome-mediated delivery of antiviral agents to human immunodeficiency virus-infected cells. Mol. Membrane Biol. 16:1999;111-118
23. Düzgüneş N., Simões S., Slepushkin V., Pretzer E., Rossi J.J., De Clercq E., Antao V.P., Collins M.L., Pedroso de Lima M.C. Enhanced inhibition of HIV-1 replication in macrophages by antisense oligonucleotides, ribozymes and acyclic oligonucleotide phosphonate analogs delivered in pH-sensitive liposomes. Nucleosides Nucleotides Nucleic Acids. 20:2001a;515-523
24. Düzgüneş N., Simões S., Konopka K., Rossi J.J., Pedroso de Lima M.C. Delivery of novel macromolecular drugs against HIV-1. Expert Opin. Biol. Ther. 1:2001b;949-970
25. Dykxhoorn D.M., Novina C.D., Sharp P.A. Killing the messenger: Short RNAs that silence gene expression. Nat. Rev. Mol. Cell. Biol. 4:2003;457-467
26. FitzGerald D.J. Construction of immunotoxins using Pseudomonas exotoxin A. Methods Enzymol. 151:1987;139-145
27. Flasher D., Konopka K., Chamow S., Ashkenazi A., Dazin P., Pretzer E., Düzgüneş N. Liposome targeting to human immunodeficiency virus type 1-infected cells via recombinant soluble CD4 and CD4-immunoadhesin (CD4-IgG). Biochim. Biophys. Acta. 1194:1994;185-196
28. Giovannangeli C., Diviacco S., Labrousse V., Gryaznov S., Charneau P., Hélène C. Accessibility of nuclear DNA to triplex-forming oligonucleotides: The integrated HIV-1 provirus as a target. Proc. Natl. Acad. Sci. USA. 94:1997;79-84
29. Heath T.D. Covalent attachment of proteins to liposomes. Methods Enzymol. 149:1987;111-119
30. Henke C., Steinem C., Janshoff A., Steffan G., Luftmann H., Sieber M., Galla H.-J. Self-assembled monolayers of monofunctionalized cyclodextrins onto gold: A mass spectrometric characterization and impedance analysis of host-guest interaction. Anal. Chem. 68:1996;3158-3165
31. Jameson B.A., Rao P.E., Kong L.I., Hahn B.H., Shaw G.M., Hood L.E., Kent S.B.H. Location and chemical synthesis of a binding site for HIV-1 on the CD4 protein. Science. 240:1988;1335-1339
32. Johnson V.A., Byington R.E. Infectivity assay (virus yield assay). Aldovoni A., Walker B.D. "Techniques in HIV Research" 1990;71-76 Stockton Press, New York
33. Jonak Z.L., Clark R.K., Matour D., Trulli S., Craig R., Henri E., Lee E.V., Greig R., Debouck C. A human lymphoid recombinant cell line with functional human immunodeficiency virus type 1 envelope. AIDS Res. Hum. Retroviruses. 9:1993;23-32
34. Kay J., Dunn B.M. Viral proteinases: Weakness in strength. Biochim. Biophys. Acta. 1048:1990;1-18
35. Konopka K., Davis B.R., Larsen C.E., Alford D.R., Debs R.J., Düzgüneş N. Liposomes modulate human immunodeficiency virus infectivity. J. Gen. Virol. 71:1990;2899-2907
36. Konopka K., Davis B.R., Larsen C.E., Düzgüneş N. Anionic liposomes inhibit human immunodeficiency virus type 1 (HIV-1) infectivity in CD4+ A3.01 and H9 cells. Antiviral Chem. Chemother. 4:1993a;179-187
37. IIIB). Virology. 193:1993b;877-887
38. Konopka K., Pretzer E., Felgner P.L., Düzgüneş N. Human immunodeficiency virus type-1 (HIV-1) infection increases the sensitivity of macrophages and THP-1 cells to cytotoxicity by cationic liposomes. Biochim. Biophys. Acta. 1312:1996;186-196
39. Konopka K., Rossi J.J., Swiderski P., Slepushkin V.A., Düzgüneş N. Delivery of anti-HIV-1 ribozyme into HIV-infected cells via cationic liposomes. Biochim. Biophys. Acta. 1372:1998;55-68
40. Larsen C.E., Nir S., Alford D.R., Jennings M., Lee K.-D., Düzgüneş N. Human immunodeficiency virus type 1 (HIV-1) fusion with model membranes: Kinetic analysis and the effects of pH and divalent cations. Biochim. Biophys. Acta. 1147:1993;223-236
41. Lebo R.V., Bruce B.D., Dazin P.F., Payan D.G. Design and application of a versatile triple-laser cell and chromosome sorter. Cytometry. 8:1993;71-82
42. Lifson J.D. Fusion of human immunodeficiency virus-infected cells with uninfected cells. Methods Enzymol. 221:1993;3-12
43. Lisziewicz J., Sun D., Klotman M., Agrawal S., Zamecnik P., Gallo R. Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: An in vitro model for treatment. Proc. Natl. Acad. Sci. USA. 89:1992;11209-11213
44. Lisziewicz J., Sun D., Weichold F.F., Thierry A.R., Lusso P., Tang J., Gallo R.C., Agrawal S. Antisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cells. Proc. Natl. Acad. Sci. USA. 91:1994;7942-7946
45. Litzinger D.C., Brown J.M., Wala I., Kaufman S.A., Van G.Y., Farrell C.L., Collins D. Fate of cationic liposomes and their complex with oligonucleotide in vivo. Biochim. Biophys. Acta. 1281:1996;139-149
46. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;267-275
47. Martin F.J., Papahadjopoulos D. Irreversible coupling of immunoglobulin fragments to preformed vesicles. An improved method for liposome targeting. J. Biol. Chem. 257:1982;286-288
48. Meltzer M.S., Skillman D.R., Gomatos P.J., Kalter D.C., Gendelman H.E. Role of mononuclear phagocytes in the pathogenesis of human immunodeficiency virus infection. Annu. Rev. Immunol. 8:1990;169-194
49. Naesens L., Balzarini J., De Clercq E. Acyclic adenine nucleoside phosphonates in plasma determined by high-performance liquid chromatography with fluorescence detection. Clin. Chem. 38:1992;480-485
50. Pooga M., Land T., Bartfai T., Langel Ü. PNA oligomers as tools for specific modulation of gene expression. Biomol. Eng. 17:2001;183-192
51. Praseuth D., Guieysse A.L., Hélène C. Triple helix formation and the antigene strategy for sequence-specific control of gene expresssion. Biochim. Biophys. Acta. 1489:1999;181-206
52. Pretzer E., Flasher D., Düzgüneş N. Inhibition of human immunodeficiency virus type-1 replication in macrophages and H9 cells by free or liposome-encapsulated L-689,502, an inhibitor of the viral protease. Antiviral Res. 34:1997;1-15
53. Riddles P.W., Blakeley R.L., Zerner B. Reassessment of Ellman's reagent. Methods Enzymol. 91:1983;49-60
54. Robins T., Plattner J. HIV protease inhibitors: Their anti-HIV activity and potential role in treatment. J. Acquir. Immune Defic. Syndr. 6:1993;162-170
55. Ropert C., Lavignon M., Dubernet C., Couvreur P., Malvy C. Oligonucleotides encapsulated in pH sensitive liposomes are efficient toward Friend retrovirus. Biochem. Biophys. Res. Commun. 183:1992;879-885
56. Seidman M.M., Glazer P.M. The potential for gene repair via triple helix formation. J. Clin. Invest. 112:2003;487-494
57. Shi F., Hoekstra D. Effective intracellular delivery of oligonucleotides in order to make sense of antisense. J. Control. Release. 97:2004;189-209
58. Shi F., Wasungu L., Nomden A., Stuart M.C., Polushkin E., Engberts J.B., Hoekstra D. Interference of poly(ethylene glycol)-lipid analogues with cationic-lipid-mediated delivery of oligonucleotides; role of lipid exchangeability and non-lamellar transitions. Biochem. J. 366:2002;333-341
59. Simões S., Slepushkin V., Düzgüneş N., Pedroso de Lima M.C. On the mechanisms of internalization and intracellular delivery mediated by pH-sensitive liposomes. Biochim. Biophys. Acta. 1515:2001;23-37
60. Slepushkin V.A., Salem I.I., Andreev S.M., Dazin P., Düzgü neş N. Targeting of liposomes to HIV-1 infected cells by peptides derived from the CD4 receptor. Biochem. Biophys. Res. Commun. 227:1996;827-833
61. Slepushkin V.A., Simões S., Dazin P., Newman M.S., Guo L.S., Pedroso de Lima M.C., Düzgüneş N. Sterically stabilized pH-sensitive liposomes: Intracellular delivery of aqueous contents and prolonged circulation in vivo. J. Biol. Chem. 272:1997;2382-2388
62. Slepushkin V., Simões S., Pedroso de Lima M.C., Düzgüneş N. Sterically stabilized pH-sensitive liposomes. Methods Enzymol. 387:2004;134-147
63. Song L.Y., Ahkong Q.F., Rong Q., Wang Z., Ansell S., Hope M.J., Mui B. Characterization of the inhibitory effect of PEG-lipid conjugates on the intracellular delivery of plasmid and antisense DNA mediated by cationic lipid liposomes. Biochim. Biophys. Acta. 1558:2002;1-13
64. Steffan G., Galla H.-J., Düzgüneş N., Henke C. Sterinverknüpfte, anionische cyclodextrinderivative und deren verwendung in arzneimittelformulierungen. 2000;. German Patent DE 198 14 815 C2
65. Stein C.A., Neckers L.M., Nair B.C., Mumbauer S., Hoke G., Pal R. Phosphorothioate oligodeoxycytidine interferes with binding of HIV-1 gp1/20 to CD4. J. Acquir. Immune Defic. Synd. 4:1991;686-693
66. Stephens A.C., Rivers R.P. Antisense oligonucleotide therapy in cancer. Curr. Opin. Mol. Ther. 5:2003;118-122
67. Stevenson M. Dissecting HIV-1 through RNA interference. Nat. Rev. Immunol. 3:2003;851-858
68. Straubinger R.M., Düzgüneş N., Papahadjopoulos D. pH-Sensitive lioposomes mediate cytoplasmic delivery of encapsulated macromolecules. FEBS Lett. 179:1985;148-154
69. Szoka F. Jr., Papahadjopoulos D. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc. Natl. Acad. Sci. USA. 75:1978;4194-4198
70. Thompson W.J., Fitzgerald P.M.D., Holloway M.K., Emini E.A., Darke P.L., McKeever B.M., Schleif W.A., Quintero J.C., Zugay J.A., Tucker T.J., Schwering J.E., Homnick C.F., Nunberg J., Springer J.P., Huff J.R. Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1′ phenyl substituents: X-ray crystal structure assisted design. J. Med. Chem. 35:1992;1685-1701
71. Torchilin V.P., Zhou F., Huang L. pH-sensitive liposomes. J. Liposome Res. 3:1993;201-255
72. Vasquez K.M., Narayanan L., Glazer P.M. Specific mutations induced by triplex-forming oligonucleotides in mice. Science. 290:2000;530-533
73. Wagner R.W., Flanagan W.M. Antisense technology and prospects for therapy of viral infections and cancer. Mol. Med. Today. 3:1997;31-38
74. Weichold F.F., Lisziewicz J., Zeman R.A., Nerurkar L.S., Agrawal S., Reitz M.S. Jr., Gallo R.C. Antisense phosphorothioate oligodeoxynucleotides alter HIV type 1 replication in cultured human macrophages and peripheral blood mononuclear cells. AIDS Res. Hum. Retroviruses. 11:1995;863-868
75. Zelphati O., Imbach J.-L., Signoret N., Zon G., Rayner B., Leserman L. Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms. Nucleic Acids Res. 22:1994;4307-4314